These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 28235153)

  • 21. Mutations in LRRK2 impair NF-κB pathway in iPSC-derived neurons.
    López de Maturana R; Lang V; Zubiarrain A; Sousa A; Vázquez N; Gorostidi A; Águila J; López de Munain A; Rodríguez M; Sánchez-Pernaute R
    J Neuroinflammation; 2016 Nov; 13(1):295. PubMed ID: 27863501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impaired serine metabolism complements LRRK2-G2019S pathogenicity in PD patients.
    Nickels SL; Walter J; Bolognin S; Gérard D; Jaeger C; Qing X; Tisserand J; Jarazo J; Hemmer K; Harms A; Halder R; Lucarelli P; Berger E; Antony PMA; Glaab E; Hankemeier T; Klein C; Sauter T; Sinkkonen L; Schwamborn JC
    Parkinsonism Relat Disord; 2019 Oct; 67():48-55. PubMed ID: 31621607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative blood transcriptome analysis in idiopathic and LRRK2 G2019S-associated Parkinson's disease.
    Infante J; Prieto C; Sierra M; Sánchez-Juan P; González-Aramburu I; Sánchez-Quintana C; Berciano J; Combarros O; Sainz J
    Neurobiol Aging; 2016 Feb; 38():214.e1-214.e5. PubMed ID: 26675812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Generation of 2 induced pluripotent stem cell lines derived from patients with Parkinson's disease carrying LRRK2 G2385R variant.
    Cheng YC; Huang CY; Ho MC; Hsu YH; Syu SH; Lu HE; Lin HI; Lin CH; Hsieh PCH
    Stem Cell Res; 2018 Apr; 28():1-5. PubMed ID: 29414410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurite Collapse and Altered ER Ca
    Korecka JA; Talbot S; Osborn TM; de Leeuw SM; Levy SA; Ferrari EJ; Moskites A; Atkinson E; Jodelka FM; Hinrich AJ; Hastings ML; Woolf CJ; Hallett PJ; Isacson O
    Stem Cell Reports; 2019 Jan; 12(1):29-41. PubMed ID: 30595548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation.
    Zhao Y; Keshiya S; Perera G; Schramko L; Halliday GM; Dzamko N
    Neurobiol Dis; 2020 Oct; 144():105049. PubMed ID: 32800998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parkinson's disease in a dish - Using stem cells as a molecular tool.
    Badger JL; Cordero-Llana O; Hartfield EM; Wade-Martins R
    Neuropharmacology; 2014 Jan; 76 Pt A():88-96. PubMed ID: 24035919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LRRK2 Expression Is Deregulated in Fibroblasts and Neurons from Parkinson Patients with Mutations in PINK1.
    Azkona G; López de Maturana R; Del Rio P; Sousa A; Vazquez N; Zubiarrain A; Jimenez-Blasco D; Bolaños JP; Morales B; Auburger G; Arbelo JM; Sánchez-Pernaute R
    Mol Neurobiol; 2018 Jan; 55(1):506-516. PubMed ID: 27975167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In Vitro Modeling of Leucine-Rich Repeat Kinase 2 G2019S-Mediated Parkinson's Disease Pathology.
    Vermilyea SC; Emborg ME
    Stem Cells Dev; 2018 Jul; 27(14):960-967. PubMed ID: 29402177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.
    Howlett EH; Jensen N; Belmonte F; Zafar F; Hu X; Kluss J; Schüle B; Kaufman BA; Greenamyre JT; Sanders LH
    Hum Mol Genet; 2017 Nov; 26(22):4340-4351. PubMed ID: 28973664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-variance RNAs identify Parkinson's disease molecular signature in blood.
    Chikina MD; Gerald CP; Li X; Ge Y; Pincas H; Nair VD; Wong AK; Krishnan A; Troyanskaya OG; Raymond D; Saunders-Pullman R; Bressman SB; Yue Z; Sealfon SC
    Mov Disord; 2015 May; 30(6):813-21. PubMed ID: 25786808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytogenetic Analysis of the Results of Genome Editing on the Cell Model of Parkinson's Disease.
    Vetchinova AS; Simonova VV; Novosadova EV; Manuilova ES; Nenasheva VV; Tarantul VZ; Grivennikov IA; Khaspekov LG; Illarioshkin SN
    Bull Exp Biol Med; 2018 Jul; 165(3):378-381. PubMed ID: 30006877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Derivation, Characterization, and Neural Differentiation of Integration-Free Induced Pluripotent Stem Cell Lines from Parkinson's Disease Patients Carrying SNCA, LRRK2, PARK2, and GBA Mutations.
    Momcilovic O; Sivapatham R; Oron TR; Meyer M; Mooney S; Rao MS; Zeng X
    PLoS One; 2016; 11(5):e0154890. PubMed ID: 27191603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generation of gene-corrected iPSCs line (KEIUi001-A) from a PARK8 patient iPSCs with familial Parkinson's disease carrying the I2020T mutation in LRRK2.
    Ohta E; Sone T; Ukai H; Hisamatsu T; Kitagawa T; Ishikawa M; Nagai M; Ueda HR; Obata F; Okano H
    Stem Cell Res; 2020 Dec; 49():102073. PubMed ID: 33181472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers.
    Dzamko N; Rowe DB; Halliday GM
    Mov Disord; 2016 Jun; 31(6):889-97. PubMed ID: 26917005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurite Aggregation and Calcium Dysfunction in iPSC-Derived Sensory Neurons with Parkinson's Disease-Related LRRK2 G2019S Mutation.
    Schwab AJ; Ebert AD
    Stem Cell Reports; 2015 Dec; 5(6):1039-1052. PubMed ID: 26651604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Parkinson's-disease-associated mutation LRRK2-G2019S alters dopaminergic differentiation dynamics via NR2F1.
    Walter J; Bolognin S; Poovathingal SK; Magni S; Gérard D; Antony PMA; Nickels SL; Salamanca L; Berger E; Smits LM; Grzyb K; Perfeito R; Hoel F; Qing X; Ohnmacht J; Bertacchi M; Jarazo J; Ignac T; Monzel AS; Gonzalez-Cano L; Krüger R; Sauter T; Studer M; de Almeida LP; Tronstad KJ; Sinkkonen L; Skupin A; Schwamborn JC
    Cell Rep; 2021 Oct; 37(3):109864. PubMed ID: 34686322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Leucine-Rich Repeat Kinase 2 Influences Fate Decision of Human Monocytes Differentiated from Induced Pluripotent Stem Cells.
    Speidel A; Felk S; Reinhardt P; Sterneckert J; Gillardon F
    PLoS One; 2016; 11(11):e0165949. PubMed ID: 27812199
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation of induced pluripotent stem cells (NIMHi001-A) from a Parkinson's disease patient of East Indian ethnicity carrying LRRK2 I1371V variant.
    Datta I; Sowmithra ; Jagtap S; Potdar C; Yadav R; Pal P
    Stem Cell Res; 2020 Apr; 44():101768. PubMed ID: 32244201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generation of iPSCs carrying a common LRRK2 risk allele for in vitro modeling of idiopathic Parkinson's disease.
    Marrone L; Bus C; Schöndorf D; Fitzgerald JC; Kübler M; Schmid B; Reinhardt P; Reinhardt L; Deleidi M; Levin T; Meixner A; Klink B; Glatza M; Gloeckner CJ; Gasser T; Sterneckert J
    PLoS One; 2018; 13(3):e0192497. PubMed ID: 29513666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.